904 studies found for:    Open Studies | "Stem Cell Transplantation"
Show Display Options
Rank Status Study
21 Not yet recruiting Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Hepatosplenic T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Stage II Angioimmunoblastic T-cell Lymphoma;   Stage II Enteropathy-Associated T-Cell Lymphoma;   Stage III Angioimmunoblastic T-cell Lymphoma;   Stage III Enteropathy-Associated T-Cell Lymphoma;   Stage IV Angioimmunoblastic T-cell Lymphoma;   Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Etoposide;   Drug: Prednisone;   Drug: Lenalidomide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
22 Recruiting Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1;   Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Burkitt Lymphoma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma
Interventions: Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
23 Recruiting Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
24 Recruiting Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
Interventions: Radiation: Radiation;   Drug: Cyclophosphamide;   Biological: Donor Lymphocyte Infusion (DLI);   Biological: Haploidentical Stem Cell Transplantation
25 Recruiting Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Radiation: Iodine I 131 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis
26 Recruiting Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
Condition: MYOPATHY
Intervention: Biological: hematopoietic stem cell transplantation
27 Recruiting Evaluation of Autologous Mesenchymal Stem Cell Transplantation in Chronic Spinal Cord Injury: a Pilot Study
Condition: Spinal Cord Injury
Intervention: Other: Mesenchymal stem cell transplantation
28 Recruiting A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma
Condition: Ewing Sarcoma
Interventions: Biological: allogeneic stem cell transplantation;   Drug: Clyclophosphamide;   Drug: Fludarabina;   Drug: Busulfan;   Drug: Melphalan
29 Recruiting O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Conditions: Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Biological: Filgrastim;   Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: O6-Benzylguanine;   Drug: Plerixafor;   Radiation: Proton Beam Radiation Therapy;   Drug: Temozolomide
30 Recruiting Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Ischemic Stroke
Condition: Stroke
Intervention: Genetic: Intravenous stem cell transplantation
31 Recruiting Multi Donor Mismatched Stem Cell Transplantation (MDT)
Condition: Graft-Versus-Host Disease
Intervention: Procedure: Multi donor stem cell transplantation
32 Unknown  Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients
Condition: Liver Cirrhosis
Interventions: Procedure: stem cell transplantation through interventional procedure;   Drug: antiviral therapy (lamivudine, other antiviral drugs)
33 Recruiting Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Conditions: Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Childhood Acute Erythroid Leukemia;   Childhood Acute Megakaryoblastic Leukemia;   Childhood Acute Monoblastic Leukemia;   Childhood Acute Monocytic Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myeloid Leukemia With Maturation;   Childhood Acute Myeloid Leukemia With Minimal Differentiation;   Childhood Acute Myeloid Leukemia Without Maturation;   Childhood Acute Myelomonocytic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Clofarabine;   Drug: Cyclosporine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Total-Body Irradiation
34 Recruiting Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic and Lymphoid Cell Neoplasm;   Indolent Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Hodgkin Lymphoma;   Small Lymphocytic Lymphoma;   T-Cell Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
35 Unknown  Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Procedure: Immunosuppression and autologous stem cell transplantation;   Procedure: Autologous hematopoietic stem cell transplantation
36 Recruiting Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Conditions: Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Diffuse Large B-Cell Lymphoma;   Aggressive Non-Hodgkin Lymphoma;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Diffuse Large B -Cell Lymphoma;   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Stage I Adult Hodgkin Lymphoma;   Stage I Aggressive Adult Non-Hodgkin Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Diffuse Large B-Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Contiguous Adult Aggressive Non-Hodgkin Lymphoma;   Stage II Contiguous Mantle Cell Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage II Non-Contiguous Aggressive Adult Non-Hodgkin Lymphoma;   Stage II Non-Contiguous Mantle Cell Lymphoma;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Aggressive Adult Non-Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Diffuse Large B-Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Aggressive Adult Non-Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Diffuse Large B-Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Drug: Atorvastatin Calcium;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
37 Recruiting Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Essential Thrombocythemia;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Polycythemia Vera;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
38 Recruiting Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Busulfan;   Drug: Palifermin;   Drug: Panobinostat;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Dexamethasone acetate;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Procedure: Stem Cell Transplant
39 Recruiting JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Enzyme Inhibitor Therapy;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
40 Recruiting Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years